APP
JAZZ icon

Avantax Planning Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Avantax Planning Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-120
Closed -$20K – 755
2018
Q3 		$20K Buy
+120
New +$20.6K ﹤0.01% 701

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Avantax Planning Partners's JAZZ Position: Q4 2018 in Review

Avantax Planning Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2018, closing a stake of 120 shares — an estimated $20K sold.

Avantax Planning Partners first reported a position in JAZZ in Q3 2018 and held it in 1 quarter. The position peaked at $20K in Q3 2018. 417 funds tracked by Wall St. Rank hold JAZZ as of Q4 2018.

  • Avantax Planning Partners reported no remaining Jazz Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 120 Jazz Pharmaceuticals shares in Q4 2018, an estimated $20K.
  • Avantax Planning Partners first reported a position in Jazz Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Avantax Planning Partners's Jazz Pharmaceuticals position peaked at $20K in Q3 2018.
  • 417 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.